ArticleeLife2014
A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites.
Article in eLife, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03163121 (Safety and Protective Efficacy of Genetically Attenuated Pf∆b9∆Slarp), which is not on this map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Protective Efficacy of Genetically Attenuated Pf∆b9∆Slarp (PfSPZ-GA1) Malaria Parasites in Healthy Dutch Volunteers
Who cites it
52 citing papers in PubMed.
- Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial.Nature medicine · 2025Trial
- Next-Generation Vaccines Against Neglected Diseases: New Promises from Genetically Modified Live-Attenuated Parasites and RNA Vaccines.Microorganisms · 2026Review
- Replication stress increases de novo CNVs across the malaria parasite genome.Nucleic acids research · 2026Article
- The path from early- to late-liver stage arresting genetically attenuated parasites as a malaria vaccination strategy.NPJ vaccines · 2025Review
- Replication stress increases de novo CNVs across the malaria parasite genome.bioRxiv : the preprint server for biology · 2025Article
- A Plasmodium LARC GAP provides preerythrocytic, stage and species transcending protection in mice.NPJ vaccines · 2025Article
- Controlled human malaria infection studies: insights into recent advances and key immunological and ethical implementation lessons.Frontiers in immunology · 2025Review
- A conserved Plasmodium nuclear protein is critical for late liver stage development.Communications biology · 2024Article
- A Plasmodium late liver stage arresting GAP provides superior protection in mice.NPJ vaccines · 2024Article
- Whole-sporozoite malaria vaccines: where we are, where we are going.EMBO molecular medicine · 2024Review
- Experimental vaccination by single dose sporozoite injection of blood-stage attenuated malaria parasites.EMBO molecular medicine · 2024Article
- The effect of dosage on the protective efficacy of whole-sporozoite formulations for immunization against malaria.NPJ vaccines · 2023Article
- Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver.NPJ vaccines · 2022Article
- Live Vaccination with Blood-StageVaccines · 2022Article
- Structure of the Pf12 and Pf41 heterodimeric complex ofFEMS microbes · 2022Article
- Five decades of clinical assessment of whole-sporozoite malaria vaccines.Frontiers in immunology · 2022Review
- Whole-genome analysis of Malawian Plasmodium falciparum isolates identifies possible targets of allele-specific immunity to clinical malaria.PLoS genetics · 2021Article
- Immune responses to malaria pre-erythrocytic stages: Implications for vaccine development.Parasite immunology · 2021Review
- Establishment of a stable transfection method in Babesia microti and identification of a novel bidirectional promoter of Babesia microti.Scientific reports · 2020Article
- Pre-Erythrocytic Vaccines against Malaria.Vaccines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
A highly efficacious pre-erythrocytic stage vaccine would be an important tool for the control and elimination of malaria but is currently unavailable. High-level protection in humans can be achieved by experimental immunization with Plasmodium falciparum sporozoites attenuated by radiation or under anti-malarial drug coverage. Immunization with genetically attenuated parasites (GAP) would be an attractive alternative approach. In this study, we present data on safety and protective efficacy using sporozoites with deletions of two genes, that is the newly identified b9 and slarp, which govern independent and critical processes for successful liver-stage development. In the rodent malaria model, PbΔb9ΔslarpGAP was completely attenuated showing no breakthrough infections while efficiently inducing high-level protection. The human PfΔb9ΔslarpGAP generated without drug resistance markers were infective to human hepatocytes in vitro and to humanized mice engrafted with human hepatocytes in vivo but completely aborted development after infection. These findings support the clinical development of a PfΔb9ΔslarpSPZ vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.